Literature DB >> 14648702

Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells.

Susanna Miettinen1, Merja H Ahonen, Yan-Ru Lou, Tommi Manninen, Pentti Tuohimaa, Heimo Syvälä, Timo Ylikomi.   

Abstract

Vitamin D and its analogues are potent regulators of cell growth and differentiation both in vivo and in vitro. We studied the effects of 25-hydroxyvitamin D(3) [25(OH)D(3)], 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and vitamin D analogue, EB 1089, on the growth of a human ovarian cancer cell line, OVCAR-3. We also studied the expression of vitamin D metabolising enzymes 24-hydroxylase (24OHase) and 1alpha-hydroxylase (1alphaOHase). Our results showed that high concentrations (10 and 100 nM) of 1,25(OH)(2)D(3) inhibited a cell proliferation, whereas low concentration (0.1 nM) stimulated growth of the OVCAR-3 cells. In the concentration range of 10-500 nM a prohormone, 25(OH)D(3), stimulated growth. An amount of 1 nM EB 1089 and 100 nM 1,25(OH)(2)D(3) inhibited growth with an equal magnitude. The expression of 24OHase was strongly induced by 1,25(OH)(2)D(3) and EB 1089 in OVCAR-3 cells, and analysis of vitamin D metabolites showed the functionality of 24OHase. An inhibition of 24OHase activity with a novel 24OHase inhibitor enhanced growth-inhibiting effects of 1,25(OH)(2)D(3) and suppressed the growth stimulation of 100 nM 25(OH)D(3). We also report the expression of a vitamin D activating enzyme, 1alphaOHase, in 7 ovarian cancer cell lines. The production of 1,25(OH)(2)D(3) in OVCAR-3 cells was low, possibly due to an extensive activity of 24OHase or a low 1alphaOHase activity. These results suggest that in ovarian cancer cells vitamin D metabolizing enzymes might play a key role in modulating the growth response to vitamin D. The possible mitogenic effects of vitamin D should be considered when evaluating treatment of ovarian cancer with vitamin D. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14648702     DOI: 10.1002/ijc.11520

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis.

Authors:  Xiaohui Zhang; Pengfei Li; Junying Bao; Santo V Nicosia; Honggang Wang; Steven A Enkemann; Wenlong Bai
Journal:  J Biol Chem       Date:  2005-08-10       Impact factor: 5.157

2.  Clinical and Metabolic Response to Vitamin D Supplementation in Endometrial Hyperplasia: a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Zohreh Tabassi; Sedigheh Bagheri; Mansooreh Samimi; Hamid Reza Gilasi; Fereshteh Bahmani; Maryam Chamani; Zatollah Asemi
Journal:  Horm Cancer       Date:  2017-03-10       Impact factor: 3.869

3.  The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells.

Authors:  Zheng Shen; Xiaohui Zhang; Jinfu Tang; Ravi Kasiappan; Umesh Jinwal; Pengfei Li; Shan Hann; Santo V Nicosia; Jie Wu; Xiaohong Zhang; Wenlong Bai
Journal:  Mol Cell Endocrinol       Date:  2011-03-30       Impact factor: 4.102

4.  Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.

Authors:  Wei Zheng; Kim N Danforth; Shelley S Tworoger; Marc T Goodman; Alan A Arslan; Alpa V Patel; Marjorie L McCullough; Stephanie J Weinstein; Laurence N Kolonel; Mark P Purdue; Xiao-Ou Shu; Kirk Snyder; Emily Steplowski; Kala Visvanathan; Kai Yu; Anne Zeleniuch-Jacquotte; Yu-Tang Gao; Susan E Hankinson; Chinonye Harvey; Richard B Hayes; Brian E Henderson; Ronald L Horst; Kathy J Helzlsouer
Journal:  Am J Epidemiol       Date:  2010-06-18       Impact factor: 4.897

5.  Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies.

Authors:  Shelley S Tworoger; Margaret A Gates; Margaret A Gate; I-Min Lee; Julie E Buring; Linda Titus-Ernstoff; Daniel Cramer; Susan E Hankinson
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

6.  25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue.

Authors:  Ulrika Segersten; Pernille Kaae Holm; Peyman Björklund; Ola Hessman; Hans Nordgren; Lise Binderup; Göran Akerström; Per Hellman; Gunnar Westin
Journal:  Breast Cancer Res       Date:  2005-10-06       Impact factor: 6.466

Review 7.  Vitamin D and Ovarian Cancer: Systematic Review of the Literature with a Focus on Molecular Mechanisms.

Authors:  Andraž Dovnik; Nina Fokter Dovnik
Journal:  Cells       Date:  2020-02-01       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.